Relationship between BCL-2 Oncogene Expression and Apoptosis in a Human Leukemia T Cell Line by Hedjbeli, Sascha
Loyola University Chicago 
Loyola eCommons 
Master's Theses Theses and Dissertations 
1995 
Relationship between BCL-2 Oncogene Expression and Apoptosis 
in a Human Leukemia T Cell Line 
Sascha Hedjbeli 
Loyola University Chicago 
Follow this and additional works at: https://ecommons.luc.edu/luc_theses 
 Part of the Biology Commons 
Recommended Citation 
Hedjbeli, Sascha, "Relationship between BCL-2 Oncogene Expression and Apoptosis in a Human 
Leukemia T Cell Line" (1995). Master's Theses. 4113. 
https://ecommons.luc.edu/luc_theses/4113 
This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It 
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more 
information, please contact ecommons@luc.edu. 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. 
Copyright © 1995 Sascha Hedjbeli 
LOYOLA UNIVERSITY CHICAGO 
RELATIONSHIP BETWEEN BCL-2 ONCOGENE EXPRESSION AND 
APOPTOSIS IN A HUMAN LEUKEMIA T CELL LINE 
A THESIS SUBMITTED TO 
THE FACULTY OF THE GRADUATE SCHOOL 
IN CANDIDACY FOR THE DEGREE OF 
MASTER OF SCIENCE 





Copyright by Sascha Hedjbeli, 1995 
All rights reserved. 
11 
ACKNOWLEDGEMENTS 
I would like to express my thanks to the members of my committee, Drs. Ian 
Boussy and William J. Wasserman. They were the source of helpful advice, guidance, 
occasional sarcasm, and support. 
Heartfelt thanks go out to the entire Department of Biology, because everyone in 
it made my stint as a graduate student very enjoyable and memorable. I would like to 
send out special thanks to some extra-special graduate students--James Chaveriat, Lynne 
Marie Ross-Darrus, Patrick Donovan, Melissa Leone, Jeffrey Panella, Kathy Rezai, 
Suganthi Ramakrishnan, Donna Santucci, and James Schavocky. Good luck to you all! 
I would also like to acknowledge the charisma, humor, wackiness, and wit of Dr. John 
Janssen. Finally, to Drs. Fred Wezeman and Roberta Lammers--thank you so much for 
allowing me to explore my teaching abilities and for helping me realize my aspirations. 
Endless thanks are proffered to the laboratory of Dr. Thomas Ellis at the Loyola 
Medical Center, especially to Ms. Patricia Simms for hours of flow cytometric analyses. 
Finally, my biggest thanks go out to my advisor, Dr. Holden T. Maecker. Two 
years ago, he had the courage to bring in a total novice (me!) into his laboratory. His 
guidance, patience, and training have exemplified the true meaning of an advisor. He 
has taught me so many things which will remain imbedded within me for the rest of my 
life. Thanks a million, Holden, and best wishes at Stanford! 
111 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .................................. iii 
LIST OF FIGURES ................................... · .... vi 
Chapter 
I. INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Literature Review . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
The Purpose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 
II. MATERIALS AND METHODS ..................... 14 
Experimental Design ......................... 14 
Cell Lines ........ : ...................... 16 
Cell Viability Assays . . . . . . . . . . . . . . . . . . . . . . . . . 17 
Monoclonal Antibodies . . . . . . . . . . . . . . . . . . . . . . . 17 
Flow Cytometry Analyses ...................... 18 
Immunoblotting ............................ 19 
RNA Extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 
Reverse Transcription (rt) ...................... 21 
Polymerase Chain Reaction (PCR) ................ 21 
BCL-2 Vector ............................. 21 
Restriction Endonuclease Digests . . . . . . . . . . . . . . . . . 22 
Polyacrylamide Gel Electrophoresis (PAGE) .......... 22 
Calcium Ionophore . . . . . . . . . . . . . . . . . . . . . . . . . . 22 
ill. RESULTS ................................... 23 
aTCR Monoclonal Antibody 
Induces Apoptosis in SUP-T13 Cells .............. 23 
Neither SUP-T13 Variant 
Undergoes aTCR-Mediated Apoptosis ............. 24 
SUP-T13 Cells Express BCL-2 mRNA .............. 24 
Parental SUP-T13 and Both 
Clone A3 and Clone C8 Cells Express 
Moderate Amounts of Endogenous BCL-2 .......... 26 
Histograms Indicate Consistency 
and Sensitivity of Flow Cytometry . . . . . . . . . . . . . . 27 
BCL-2 Expression does not 
Change in SUP-T13 Cells Over Time ............ 28 
iv 
BCL-2 Expression does not 
Change in SUP-T13 Variants Over Time .......... 29 
The aBCL-2 mAb is Specific for the BCL-2 Oncogene .... 30 
aCD3 mAb does not Rescue Other 
Forms of Apoptosis in SUP-T13 Cells ........ : ... 31 
Summary of Results . . . . . . . . . . . . . . . . . . . . . . . . . 31 
IV. DISCUSSION ................................. 60 
Significance of Results . . . . . . . . . . . . . . . . . . . . . . . . 60 
CONCLUSION ......................................... 71 
REFERENCES ......................................... 72 
VITA ............................................... 78 
V 
LIST OF FIGURES 
Figure Page 
1. aTCR mAb Treatment of SUP-T13 Cells ..................... 36 
2. aTCR mAb Treatment 
of SUP-T13 Variant Clone A3 Cells ...................... 38 
3. aTCR mAb Treatment 
of SUP-T13 Variant Clone C8 Cells ...................... 40 
4. rtPCR of SUP-T13 RNA and MboI 
Digests of rtPCR Amplification Products . . . . . . . . . . . . . . . . . . . 42 
5. Comparison of Endogenous 
BCL-2 Levels Between Parental and Variant 
SUP-T13 Cells Versus PBLs and EBNA 293 ................. 44 
6. Consistency and Sensitivity of Flow Cytometry for 
Detecting Changes in BCL-2 Oncoprotein Levels .............. 46 
7. BCL-2 Expression During 
Eight Hours of mAb Treatment in SUP-T13 Cells .............. 48 
8. BCL-2 Expression During Eight 
Hours of mAb Treatment in Variant Clone A3 Cells ............ 50 
9. BCL-2 Expression During Eight 
Hours of mAb Treatment in Variant Clone C8 Cells ............ 52 
10. Immunoblotting of aTCR mAb-Treated SUP-T13 Cells ............ 54 
11. aFAS mAb Treatment of SUP-T13 Cells ..................... 56 
12. Calcium Ionophore Treatment of SUP-T13 Cells ................ 58 
Vl 
Physiology proves that death is not an instantaneous, momentary phenomenon, but a very 
protracted process. Every organised being is every moment the same and not the same 
... every moment some cells of its body die and others build themselves anew. 




The mammalian immune system is constantly exposed to a very inhospitable 
environment. At any given time, it must defend against a wide variety of pathogenic 
invaders. Such invaders include viruses, bacteria, fungi, and parasites, all of which have 
the ability to lead to serious infection and/or death for the afflicted host. However, in 
normal individuals, most infections are short-lived and do not cause any permanent 
damage. A mammal's main defense against such pathogenic infections is the immune 
system. The mammalian immune system is hallmarked by extreme complexity, diversity, 
and specificity. It involves the communication between numerous types of effector cells 
and molecules, all of which eventually lead to the successful eradication of the foreign 
invader (Abbas et al., 1991; Paul et al., 1989; and Roitt et al., 1993). 
The most important of these effector cells is the thymus-derived lymphocyte, or 
T cell for short (Feldman et al., 1989). It is a leukocyte, or white blood cell, which 
arises from the lymphoid blood lineage and which matures in the thymus, hence its 
name. T cells are of utmost importance for the mammalian immune response, since they 
are the sole entities which can discriminate between self and non-self. In other words, 
they ultimately decide whether an invader is to be ignored, or whether it should be 
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attacked and destroyed. There are three known subsets of T cells (Marchalonis, 1988; 
Paul, 1989; and Roitt et al., 1993). One subset is the helper T cell, which interacts with 
another cell of the lymphoid lineage known as the B lymphocyte, or B cell, thereby 
controlling its proliferation, differentiation, and production of antibody. Helper T cells 
also help initiate cytotoxic responses, which are enacted by a second subset of T cells 
called cytotoxic T cells. This response destroys host cells that have been infected by 
viruses or intracellular bacteria. The last subset is the suppressor T cell and, as its name 
implies, it has the ability to curb an ongoing immune response. The importance of T 
cells in the human immune response is well illustrated in Acquired Immunodeficiency 
Syndrome, or AIDS. A unique characteristic of AIDS is the depletion of helper T cells. 
As a result, both antibody responses and cytotoxic responses to foreign invaders 
(regardless of how harmless) are halted. This inevitably results in severe 
immunodeficiency for the afflicted patient (Abbas et al., 1989 and Benjamani et al., 
1991). 
T cells possess a T cell receptor (TCR) on their surface. The TCR is a 
heterodimeric, disulfide-linked glycoprotein which is non-covalently linked to a complex 
of five invariant proteins, collectively known as CD3 (Feldman et al., 1989). The TCR 
can only bind to foreign invaders which have been processed into small peptide 
fragments, by antigen-presenting cells (APCs), and complexed to self major 
histocompatiblity (MHC) proteins. There are two types of MHC proteins, class I and 
class II, and they are present in every mammalian cell. MHC proteins contain a long, 
well-defined groove on their upper surface, in which fragments of foreign peptides are 
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displayed and, subsequently, recognized by the TCR. The TCRs of cytotoxic T cells 
bind to foreign peptides associated with class I MHC, and those of helper T cells bind 
to foreign peptides associated with class II MHC. The signals which result from this 
binding are transduced into the cytosol, via the CD3 protein complex (reviewed by 
Marrack and Kappler, 1990; Paul et al., 1989; and Roitt et al., 1993). 
T cells exhibit an unusual developmental and maturation scheme, most of which, 
as mentioned above, occurs in the thymus. Initially, T cells, like all other leukocytes, 
originate in the bone marrow, and they lack the leukocyte surface antigens, or clusters 
of differentiation (CD), typical of mature cells [Abbas et al., 1991]. They then migrate 
as co4- cos- (these two CD molecules are unique to T cells) thymocytes into the 
thymus, where their fate will ultimately be decided. These co4- cos- cells eventually 
acquire both CO4 and CDS cell surface expression and are denoted as co4+ cos+ 
thymocytes, making up approximately 80%-90% of the thymic population (Feldman et 
al., 1991). Rearrangement of the T cell receptor gene is the next stage in thymocyte 
maturation, followed by thymic selection. 
Thymic selection is one of the most puzzling and paradoxical aspects of T cell 
development and maturation. The paradox is how the developing thymocyte repertoire 
can be purged of both purely self-reactive cells and non-MHC-restricted cells, but still 
show a net gain of competent, self-MHC-restricted T cells (reviewed by Robey and 
Urbain, 1991 and reviewed by Finkel et al., 1991). A paradigm, which attempts to 
answer this paradox, proposes that thymocytes are selected in a two-stage process. First, 
negative selection eliminates those thymocytes whose TCR engages in high-affinity 
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interactions with self MHC antigens or with other self antigens. Second, positive 
selection allows those thymocytes, whose TCR engages in low-affinity binding with self 
MHC, to mature. Those cells with no affinity for self MHC do not undergo positive 
selection and also die. In other words, thymocytes, whose affinity for MHC will likely 
be increased by the presence of foreign peptides, are allowed to mature into fully 
competent adult T cells. 
Many factors exist which regulate and ensure the proper function of this vitally-
important immune system. One of the most important and widely-studied factors is 
programmed cell death, or apoptosis. Apoptosis comes from the Greek word which 
means "falling off." This is the term which was used by the ancient Greeks for 
describing leaves as they fell from dying trees {Tritton et al., 1994 and Wyllie 1992). 
Apoptosis, at first glance, may seem to be indicative of an extremely deleterious and 
harmful process. Ironically, apoptosis is an integral part of both embryonic and adult 
development. It is a means of eliminating unnecessary, old, or harmful cells, and it has 
been described, both in vitro and in vivo, in many different cells types and tissues, 
including neuronal cells, muscle cells, fibroblasts, and lymphocytes (Cohen, 1993; 
reviewed by Gerschenson et al., 1992; and Schwartzman et al., 1993). Apoptosis occurs 
in both invertebrates and vertebrates. It is distinguished by several irreversible 
characteristics, some of which include cytoplasmic contraction, chromatin condensation, 
plasma membrane blebbing, and endonucleosomal cleavage of DNA into 180-200 base 
pair oligonucleosomal fragments. All of these features are unique to apoptosis and are 
different from those seen in necrosis, or death which results from injury, which is 
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typified by cytoplasmic swelling, chromatin decondensation, lack of DNA cleavage, and 
reversibility in the early stages (reviewed by Bowen, 1993; reviewed by Gerschenson et 
al., 1992; reviewed by Korsmeyer, 1992; reviewed by Lee et al., 1993; and Tritton et 
al., 1994). 
Some forms of tumorigenesis have been shown to arise due to the inhibition of 
apoptosis. This is especially true in B cell leukemias and lymphomas, particularly 
follicular B cell lymphomas (Cuende et al., 1993; reviewed by King et al., 1993; Mapara 
et al., 1993; and Weiss et al., 1987). 
B cell lymphoma/leukemia two (BCL-2) is an oncogene whose expression has 
been shown to suppress apoptosis in B lymphocytes (Liu et al., 1991). However, the 
mechanism(s) of this phenomenon is(are) largely unknown. The BCL-2 oncogene is 
located on the q, or long, arm of chromosome 18. It comprises three exons (only two 
of which are coding), it is ~230 kilobases (kb) long, it generates, due to alternative 
splicing, three mRNA species (3.5, 5.5, and 8.5 kb long), and it has two oncoprotein 
products, as determined by sequence analyses of BCL-2 cDNA (Benz et al., 1993 and 
Tsujimoto et al., 1986). One of these is the alpha BCL-2 (aBCL-2) oncoprotein which 
is ~ 25-26 kilodalton (kD) in size and the other is the beta BCL-2 (/3BCL-2) oncoprotein 
which is ~ 22 kD in size, with the former being the predominant form in lymphoid cells 
(Benz et al., 1993). Both of these BCL-2 oncoproteins have 196 identical amino-
terminal amino acids, their sole difference being at the carboxy terminus due to 
alternative splicing around the second exon (Benz et al., 1993 and Tsujimoto et al., 
1986). 
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In follicular B cell lymphomas, a chromosomal translocation occurs which results 
in the juxtaposition of the BCL-2 oncogene, from its parent chromosome 18, with the 
immunoglobulin heavy chain enhancer on chromosome 14 [t(l4;18)]. This results in 
marked deregulation of the BCL-2 oncogene and, consequently, increased levels of BCL-
2 mRNA and oncoprotein (Benz et al., 1993; Hockenbery et al., 1990; and reviewed by 
Korsmeyer, 1992). McDonnel et al. (1992) have developed mice transgenic for the 
t(14;18) translocation. These mice uniformly showed atypical lymphoid hyperplasia, 
along with prolonged survival of clonal populations of mature B cells. Recent studies 
have shown that the BCL-2 oncogene does not have to be translocated in order to exert 
its anti-apoptotic effects. When transfected to overexpress BCL-2, Hockenbery et al. 
(1990) have shown that pro-B lymphocytes, which are normally dependent on interleukin-
3 (IL-3) for growth, show extended survival times upon IL-3 withdrawal. BCL-2 
deregulation at the transcriptional level has also been shown to block glucocorticoid-
induced apoptosis in pre-B lymphocytes (Alnemri et al., 1992). Studies have also shown 
that mouse fibroblast cells can become resistant to challenges with tumor necrosis factor 
(TNF), a product of the immune system which induces tumor cells to undergo apoptosis, 
upon BCL-2 overexpression via transfection (Rennet et al., 1993). These results suggest 
that BCL-2 may, indeed, have a role in preventing B cell apoptosis in vivo. 
As data from current research are becoming available, it is becoming well-
established that BCL-2 is expressed at various stages of differentiation in normal B cells. 
Chieq-Deschamps et al. (1993), Hockenbery et al. (1991) and Liu et al. (1991) each 
have demonstrated high levels of BCL-2 expression which was localized in B cell 
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germinal centers of lymph nodes. Their findings suggest that BCL-2 allows antigen-
stimulated B cells to develop and proliferate in the germinal center, thereby allowing the 
development of an antibody response towards a foreign invader. 
In contrast to B cell leukemias and lymphomas, much less research has been 
performed on T cell malignancies, with the majority of the work being performed within 
the past few years. Furthermore, many of the data are either controversial or unclear. 
Hockenbery et al. (1991) have shown that BCL-2 is expressed preferentially in the 
thymic medulla. This is where T cells migrate after being spared from apoptosis during 
thymic selection. Translocations between the BCL-2 oncogene and the TCR (the 
homologue of the immunoglobulin locus) have not been discovered; this would be 
analogous to the t(l4; 18) seen in B cell malignancies. Also, it has been shown that 
overexpression of BCL-2, via transfection, does not lessen the dependence of a T cell 
line for interleukin 2 (IL-2), a growth factor, as was seen in B cells (Nunez et al., 1990). 
These preliminary results from BCL-2 studies with T cells seem to indicate that BCL-2 
may not have exactly the same role(s) in T cells as it does in B cells. 
To further address the issue of thymic selection and whether BCL-2 can prevent 
thymocyte apoptosis and allow positive selection to ensue, several researchers have 
developed transgenic mice which overexpress the BCL-2 oncogene (Sentman et al. , 1991; 
Siegel et al., 1992; and Strasser et al., 1991). All three groups showed that immature 
thymocytes from these transgenic mice were more resistant to killing by agents which 
induce apoptosis, such as glucocorticoids, phorbol esters, calcium ionophores, and -y-
irradiation. In addition, these cells had survival advantages in culture conditions which 
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led to apoptosis, such as those lacking essential nutrients. These results indicate that 
BCL-2 does prevent thymocyte apoptosis in vitro and, consequently, may have a role in 
thymocyte positive selection. However, their data are much more debatable about 
whether BCL-2 can prevent thymocyte negative selection. For instance, Sentman et al. 
(1991) showed that T cells which recognize endogenous superantigens (e.g., autoreactive 
T cells) were found in the thymus, but not in the peripheral lymph nodes, of their 
transgenic mice. These results indicate that negative selection did occur, despite the fact 
that BCL-2 was overexpressed. Siegel et al. (1992), on the other hand, mated their 
strain of BCL-2 transgenic mice with different strains of mice whose T cells contained 
an autoreactive, or self-reactive, V{3 region to the transgenic host strain. In the resulting 
litter, however, they did observe the presence of these autoreactive T cells in peripheral 
lymph nodes. These data indicate an obvious defect in clonal deletion and negative 
selection, with this defect perhaps being due to the overexpression of BCL-2. 
Consequently, from these disparate results, it is reasonable to conclude that BCL-2 may 
not prevent all forms of thymocyte negative selection. 
Apoptosis of autoreactive thymocytes, during negative selection, is obviously a 
very important biological event for preventing autoimmunity (Smith et al., 1989). It is 
very unlikely, therefore, that it would be left under the control of just one oncogene--
BCL-2. Consequently, as with many other important biological events, a system of 
"checks-and-balances" probably exists in order to ensure that apoptosis of thymocytes 
proceeds correctly. It is not unreasonable, thus, to speculate that multiple cell-death 
pathways may exist, none of which may be necessarily under the control of BCL-2 
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(Evans, 1993; Sentman et al., 1991; and Williams et al., 1993). It is also conceivable 
that if multiple cell-death pathways exist, then multiple genes may be involved in the 
regulation of thymocyte apoptosis, with their expression being based solely on which 
pathway(s) to apoptosis is taken. Recent studies seem to corroborate this theory. For 
example, several other genes, involved with apoptosis, have been identified within the 
past few years (King et al., 1993). They are known as the 'early-response genes', and 
some examples include C-MYC (Reed et al., 1990; Shi et al., 1992; and Vaux et al., 
1988), NUR-77 (Liu et al., 1994), and FAS, which is also known as APO-1 (Itoh et al., 
1991; Mapara et al., 1993; and Takahashi et al., 1993). Two most recent newcomers 
to this family are BAX (Oltvai et al., 1993) and BCL-X (Boise et al., 1993 and 
Korsmeyer et al., 1993), both of which have sequence homology with BCL-2. BAX has 
the ability to dimerize with either itself or with BCL-2. If BAX homodimerizes, then 
increased apoptosis is observed in B cells. However, if it heterodimerizes with BCL-2, 
then decreased apoptosis is observed. BCL-X has two mRNA species which are 
generated by alternative splicing; one is BCL-XL, and the other is BCL-X8. BCL-XL 
inhibits growth factor-deprived thymocyte apoptosis just as effectively as BCL-2. BCL-
X8, on the other hand, negates the anti-apoptotic effects of BCL-2 in these same 
thymocytes. 
The Purpose 
Dr. Ronald Levy's laboratory (Stanford University, Stanford, CA) has developed 
an in vitro model for thymocyte selection and maturation. This model is based on a 
human acute lymphoblastic leukemia (ALL) T cell line named SUP-T13. SUP-T13 
10 
possesses several features typically found in immature, cortical thymocytes. First, its 
phenotype is CO2+, CD3 +, CD4 +, CD5 +, and CD8 +. Second, it has the ability to either 
lose or regain cell surface expression of its T cell receptor (TCR)/CD3 complex 
(Maecker et al., 1992). Lastly, and most importantly for the model, SUP-T13 undergoes 
apoptosis upon stimulation of its TCR with an anti-TCR (aTCR) monoclonal antibody 
(mAb). This phenomenon is analogous to negative selection of autoreactive thymocytes 
(e.g., those with high affinity for selt) [Takahashi et al., 1989]. Simultaneous treatment 
with an aCD3 mAb, however, blocks this apoptosis. This phenomenon is analogous to 
positive selection of those thymocytes which have very low affinity for self and are, thus, 
allowed to survive. 
The purpose of this thesis was to determine whether changes in BCL-2 expression 
levels are related with apoptosis in the in vitro SUP-T13 model system. If so, a putative 
role for BCL-2 may be extended to thymic selection in vivo. BCL-2 is known to inhibit 
apoptosis in many different cell types (reviewed by Korsmeyer, 1992; reviewed by Lee 
et al., 1993; Liu et al., 1991; Mariano et al., 1992; and Weiss et al., 1987). Therefore, 
the following question was posed as the specific aim of the thesis: Are BCL-2 
expression levels increased during the aCD3 mAb-mediated rescue of aTCR mAb-
induced apoptosis in SUP-T13? In an attempt to answer this question, two hypotheses 
were formulated. 
Hypothesis One (H-1) states that BCL-2 is involved in blocking SUP-T13 
apoptosis. Several predictions could be made from H-1. First, BCL-2 expression levels 
could decrease during the aTCR mAb treatments and increase during the aCD3 mAb 
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treatments. Second, BCL-2 expression levels could increase during the aTCR mAb 
treatments and decrease during the aCD3 mAb treatments. Third, BCL-2 expression 
levels could increase with both mAb treatments. Finally, BCL-2 levels could decrease 
with both mAb treatments. Based on what was known about BCL-2 from the literature 
at the time (Cuende et al., 1993; Hennet et al., 1993; and Makover et al., 1991), the 
first prediction was most likely to be true. 
Hypothesis Two (H-2) states that BCL-2 is not involved in blocking SUP-T13 
apoptosis. Only one prediction could be made from H-2. It states that BCL-2 expression 
levels may remain unchanged during both the aTCR mAb treatments and the aCD3 mab 
treatments. 
If the first prediction from H-1 were supported by the data, the strongest 
conclusion that could be drawn is that there is a relationship between increased BCL-2 
expression and the aCD3 mAb rescue of the aTCR-mediated apoptosis in SUP-T13 cells. 
In order to say that this increased BCL-2 expression is necessary or even sufficient to 
block the aTCR mAb-mediated apoptosis, further experimentation would have to be 
performed. BCL-2 expression could be increased in SUP-T13 via transfection of a BCL-
2 expression vector. Endogenous BCL-2 expression could be abrogated via an antisense 
(AS) transfection or a gene knock-out. Such manipulations would allow direct evaluation 
of BCL-2's role in SUP-13 apoptosis, but they are very complex and beyond the scope 
of this thesis. If the data support H-2, however, the conclusion would be that increased 
BCL-2 expression is not necessary for the aCD3 mAb rescue of the aTCR-mediated 
apoptosis in SUP-T13. 
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Recently, two variant SUP-T13 leukemic clones were acquired as a gift from Dr. 
Phong Le (Loyola University Medical Center, Maywood, IL). They are named SUP-TB 
Clone A3 and SUP-T13 Clone C8. Despite the presence of TCR/CD3 complexes 
(unpublished data), both of these variants are resistant to apoptosis mediated by aTCR 
mAb. As with the parental SUP-T13 cell line, BCL-2 levels will be examined in both 
of these variant clones. If the first prediction from H-1 were true, higher endogenous 
levels of BCL-2 would be expected in these variant cells and/ or levels would be expected 
to increase during the aTCR mAb treatment, since these variants are resistant to 
apoptosis induced by it. If H-2 were true, however, then these variant cells would be 
expected to have at least equal, if not lower, endogenous levels of BCL-2. 
An ancillary aim of this thesis is to determine whether the aCD3 mAb can rescue 
other forms of apoptosis which can be induced in SUP-T13 cells. Takahashi et al. 
(1989) have shown that calcium ionophores can induce apoptosis in SUP-T13 cells. 
Likewise, our laboratory has found that anti-FAS (aFAS) mAb can induce apoptosis in 
SUP-T13 cells as well (see also Takahashi et al., 1993). By elucidating which form(s) 
of apoptosis the aCD3 mAb can block, a possible pathway for apoptosis induction in 
SUP-T13 could be configured. For example, if the aCD3 mAb also rescues the calcium 
ionophore- and the aFAS-mediated forms of apoptosis, then this would indicate that there 
is a common signalling pathway for apoptosis induction in SUP-T13, suggesting the 
existence of only one apoptotic pathway--one which can be completely blocked by the 
aCD3 mAb. On the other hand, if the aCD3 mAb only rescues the aTCR-mediated 
apoptosis, then it is reasonable to conclude that at least two different pathways to 
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apoptosis exist in SUP-T13, at least one of which cannot be blocked by the aCD3 mAb. 
This would point away from the generality of apoptosis induction in SUP-T13 cells. 
Experimental Desia=n 
CHAPTER II 
MATERIALS AND METHODS 
Apoptosis of SUP-T13 leukemia cells can be induced by treatment with an aTCR 
mAb; simultaneous treatment with an aCD3 mAb, however, blocks this apoptosis 
(Takahashi et al., 1989). Hypothesis One (H-1) stated that BCL-2 is involved in 
blocking SUP-T13 apoptosis. Hypothesis Two (H-2) stated that BCL-2 is not involved 
in blocking SUP-T13 apoptosis. 
SUP-T13 cells have been shown to switch from the TCR/CD3 + phenotype to the 
TCR/CD3- phenotype, at a rate of 10-2 switches/cell/generation (Maecker et al., 1992). 
Therefore, the first step in investigating these hypotheses was the verification of SUP-
T 13 phenotype, using appropriate fluorescent-conjugated mAb and flow cytometry. Once 
TCR/CD3+ SUP-T13 cells were sorted, the next step was to determine whether SUP-T13 
cells express BCL-2 mRNA. This was elucidated by using reverse transcription of SUP-
T13 RNA and the Polymerase Chain Reaction (rtPCR) to amplify BCL-2 mRNA, 
followed by restriction endonuclease digestions of these same rtPCR products to verify 
their identity. 
With the establishment of the correct SUP-T 13 phenotype, along · with 
confirmation of BCL-2 mRNA expression, the next stage of the project was to determine 
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whether BCL-2 expression levels change during the various mAb treatments. SUP-T13 
cells were plated, in triplicate, in 24-well plates, at a concentration of 1 x 106 cells/ mL. 
One treatment group was not treated with any mAb; this served as the medium control. 
The second treatment group was treated with 50 µg/mL of aTCR mAb. The last 
treatment group was treated with 50 µg/mL of aTCR mAb, along with 50 µg/mL of 
aCD3 mAb. These concentrations of LC4 and JE6 have been previously shown to exert 
apoptotic or rescue effects, respectively, in SUP-T13 cells (Takahashi et al., 1989). 
Changes in BCL-2 expression levels were examined at the protein level, using flow 
cytometry. This was an excellent technique to use for this purpose, because it measured 
protein levels directly, and these measurements were made on a per-cell basis, thereby 
allowing for the determination of individual populations of cells. Cell viability 
experiments were performed, in parallel and in triplicate, to confirm that the various 
mAb treatments were exerting their expected effects. Viability was assessed using a 
trypan blue-exclusion assay, utilizing a standard counting procedure on a hemocytometer 
(Tharp, 1993). It has been shown previously in SUP-T13 cells that cell viability, as 
assayed by trypan blue-exclusion, is an accurate measure of apoptosis (Takahashi et al., 
1989). 
Additionally, immunoblotting was also performed as an adjuvant assay for 
identifying BCL-2 oncoprotein changes in SUP-T13 cells during the various mAb 
treatments. There are several reasons as to why this was a good technique to use. First, 
immunoblotting gave information about the aBCL-2 mAb and whether it was specific for 
the BCL-2 oncoprotein, or whether it cross-reacted with other proteins. Second, these 
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specificity data served as the foundation for all of the flow cytometry analyses, since 
those data were based solely on the specificity of the aBCL-2 mAb. Finally, 
immunoblotting showed whether BCL-2 oncoprotein levels fluctuate between two chosen 
timepoints (0 Hr. and 4 Hr.). 
The last phase of this project determined whether the aCD3 mAb can rescue other 
forms of apoptosis which could be induced in SUP-T13 cells. Two alternative means of 
inducing apoptosis in SUP-T13 cells are by the use of calcium ionophores (Takahashi et 
al., 1989) and by the use of aFAS mAb (see also Takahashi et al., 1993). Cell viability 
assays were again performed based on trypan-blue exclusion, with all treatments being 
performed in triplicate. Based on the aforementioned studies, the calcium ionophore was 
used at a concentration of 4 µM and the aF AS mAb was used at a concentration of 5 
µglmL. 
Cell Lines 
The human acute lymphoblastic leukemia (ALL) T cell line, SUP-Tl3, was 
established from a pediatric tumor. It was a gift of Dr. Stephen Smith (University of 
Chicago, Chicago, IL). The two variant cell lines, SUP-T13 Clone A3 and SUP-T13 
Clone C8, were acquired as a generous gift of Dr. Phong Le (Loyola University Medical 
Center, Maywood, IL). These variants were originally discovered during Dr. Le's 
investigations on thymic development. Dr. Le isolated them during his search for cells 
which were more susceptible to aTCR mAb killing after culture on thymic epithelial 
cells. Consequently, Clone A3 and Clone C8 were isolated as non-susceptible (Le et al., 
1994). The Epstein-Barr virus-transformed epithelial cell line, EBNA-293, was a gift 
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of Dr. Thomas Ellis (Loyola University Medical Center). Epstein-Barr virus-transformed 
cell lines have been shown, in general, to be high expressors of BCL-2 (Henderson et 
al., 1991 and reviewed by Reed, 1994). The cells were cultured in complete RPMI 1640 
medium (Sigma Chemical Co., St. Louis, MO) which was supplemented with 15 % 
newborn calf serum (NCS) [Irvine Scientific, Santa Ana, CA], glutamine (Sigma), and 
gentamicin (Gibco/BRL, Grand Island, NY). All cells were grown in an incubator at 37 
~C with 100% humidity and 5% CO2• Peripheral blood lymphocytes (PBLs) were 
isolated from a healthy donor using Ficoll-Hypaque density centrifugation. 
Cell Viability Assays 
All cells were harvested and counted, using a standard procedure (Tharp, 1993), 
on a hemocytometer (Baxter Healthcare Corp., McGaw Park, IL). Live cells were 
distinguished from dead cells based on their exclusion of a .5 % solution of the vital dye, 
trypan blue. 
Monoclonal Antibodies 
The cxTCR mAb which was used in this project was LC4. LC4 was produced in 
Dr. Ronald Levy's laboratory (Stanford University, Stanford, CA), as previously 
described (Maecker et al., 1989). The cxCD3 mAb which was used is JE6. It was 
produced in our laboratory, as previously described (Maecker et al., 1989). Some of the 
JE6 mAb was conjugated to fluorescein isothiocyanate (FITC) for use in stainings to 
verify the TCR/CD3 phenotype of the SUP-T13 cells. The cxBCL-2 mAb (clone 124) 
was commercially purchased in both unconjugated and FITC-conjugated forms (Dako 
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Inc., Carpinteria, CA). The affinity-purified goat anti-mouse/horseradish peroxidase-
conjugated antiserum was a kind gift of Dr. Anita Chong (Rush University, Chicago, 
IL). The aFAS mAb which was used was 2Dl, and it was a generous gift of Dr. Shuji 
Takahashi (Sapporo Medical University, Sapporo, Japan). 
Flow Cytometcy Analyses 
Flow cytometry was used both for verifying SUP-T13 phenotype and for 
quantitating BCL-2 oncoprotein expression levels. 
For the verification of phenotype, 5 x 10' SUP-T13 cells were harvested. The 
cells were washed once with cold phosphate buffered saline (PBS) solution which 
contained 0.02% sodium azide, then pelleted by cetrifugation at 600 g. The pellets were 
disrupted, and the cells were washed a second time with PBS which contained 2 % bovine 
serum albumin (BSA) and 0.02 % sodium azide, and pelleted. After the pellets were 
disrupted again, lOµg/mL of JE6-FITC was added, and the cells were incubated for 30 
Min. on ice and in the dark. Finally, the cells were washed twice with PBS/BSA/azide, 
pelleted, and resuspended in .5 mL of 2% paraformaldehyde in PBS (FACS fix). The 
cells were then analyzed on a Becton-Dickinson FACStar Plus flow cytometer. 
For the flow cytometric analyses of BCL-2 oncoprotein expression levels, 1 x 106 
SUP-T13 cells, taken in triplicate, were placed in 1 mL of RPMI media each, and each 
triplicate was identically treated with either no mAb (medium control), with 10 µL 
(S0µg/mL) of LC4 mAb, or with 10 µL of LC4 plus 10 µL (S0µg/mL) of JE6 mAb. 
The cells were incubated at 37 °C for one to eight hours, at which time they were 
harvested. They were then washed with cold PBS + 0.02% sodium azide and pelleted. 
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The pellets were disrupted, and the cells were then incubated for 10 Min. in FACS fix, 
with vortexing every 2 Min. Next, the cells were incubated with cold 0.5 % Triton X-
100 detergent for 10 Min. more, with vortexing every 2 Min. The cells were next 
washed with cold PBS + 0.02% sodium azide and then washed again with PBS + 2% 
BSA + 0.02% sodium azide. The pellets were disrupted, and the cells were then 
incubated, for 30 Min. in the dark and on ice, with 10 µL of aBCL-2 mAb (Dako Inc., 
Carpinteria, CA). Finally, the cells were washed with PBS + 2% BSA + 0.02% 
sodium azide, and fixed in 1 mL of FACS fix. The cells were analyzed on the FACStar 
Plus, and an average was taken of the mean channel fluorescences, which are unitless 
numbers, of each triplicate. This average was then normalized to the fluorescence of the 
untreated (medium control) cells, which was arbitrarily assigned a value of 1. 
Immunoblottina 
1 x 106 SUP-T13 cells were harvested, washed, and lysed, on ice, in 10 µL of 
Triton-X lysis buffer (0.15 M NaCl, 10 mM Tris [pH 8.0], 0.02% NaN3, 1.0% Triton-
X, lmMphenylmethylsulfonylfluoride [PMSF], 1 µg/mLpepstatin, 1:lOOaprotinin, and 
10 mM iodoacetamide) [Sigma Chemical Co., St. Louis, MO]. The cell lysates were 
subsequently centrifuged at 4,000 g for 10 Min. at 4 °C to pellet the nuclei. The 
supematants were added to 100 µL of SDS sample buffer (Laemmli, 1970) and were 
boiled for 3 Min. at 95 °C. The samples were next electrophoresed in a 15% 
polyacrylamide gel, in accordance with a standard procedure (Laemmli, 1970). The 
proteins were then electroblotted at 4 °C onto an Immobilon PVDF membrane (Milipore 
Corp., Bedford, MA) for 2 Hr. at 70 V. Next, the Immobilon PVDF membrane was 
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blocked with 1 % non-fat dairy milk and probed with a 1:500 dilution of aBCL-2 mAb 
(Dako Inc., Carpinteria, CA) in PBS, per sample, followed by a 1:2000 dilution of 
affinity-purified goat anti-mouse/horseradish peroxidase-conjugated antiserum (a kind gift 
of Dr. Anita Chong, Rush University, Chicago, IL) in PBS. Finally, the bound antibody 
was visualized by the addition of .5 mg/mL of 3,3-diaminobenzidine (DAB) [Sigma] and 
30 µL of hydrogen peroxide (H20 2) [Sigma] in PBS. 
RNA Extraction 
1 x 107 SUP-T13 cells were harvested and washed twice with warm PBS. Using 
RNase-free labware, the cells were lysed using 5 mL of Solution A, which contained 4 
M guanidium thiocyanate, 25 mM sodium citrate (pH 7.00), 0.5% sarkosyl, and .36 µL 
of /j-mercaptoethanol (Sigma Chemical Co., St. Louis, MO). The lysate was then gently 
layered onto 2.5 mL of 5.7 M CsCl and centrifuged at 12,000 g for 20 Hr. at room 
temperature. The pellet was resuspended in 600 µL of RNase-free H20 (DEPC-H20) 
[Sigma] and then transferred to a clean microfuge tube, to which 60 µL of 10 M sodium 
acetate and 1.2 mL of ice-cold ethanol (EtOH) was added. The tube was kept at -20 °C 
overnight, allowing the RNA to precipitate out. The tube was then centrifuged for 20 
Min. at 4,000 g, the supernatant was drained off carefully, and the pellet was 
resuspended in 400 µL of DEPC-H20. The RNA was extracted with 400 µL of a 
phenol:chloroform solution (1:1), followed by 400 µL of pure ether. The RNA was 
again precipitated overnight, pelleted, resuspended in EtOH, and its concentration was 
determined by taking optical density (0.D.) readings at 260 nanometers (nm) on the 
following day. 
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Reverse Transcription (rt) 
1 µg of extracted SUP-T13 RNA (see above) was incubated with an rt Master 
Mix (2.5 mM MgC12, lX PCR Buffer II [500 mM KCl and 100 mM Tris-HCl], 1.5 µL 
DEPC-H20, .5mM dGTP, .5 mM dATP, .5 mM dTTP, .5 mM dCTP, .5 U RNase 
inhibitor, 1.25 U reverse transcriptase, and 1.25 µM oligo dT) [Perkin-Elmer Cetus, 
Norwalk, CT]. The samples were overlayed with mineral oil, microfuged, and incubated 
for 20 Min. at 42 °C. in a thermocycler (MJ Research Inc., Watertown, MA). 
Polymerase Chain Reaction (PCR) 
Reverse transcription (rt) products (see above) were added to a PCR Master Mix 
(2µL of 2 mM MgC12, 4µL of lX PCR Buffer II [500 mM KCl and 100 mM Tris-HCl], 
29 µL DEPC-H20, and .25 µL Taq polymerase [2.5 U/100 µL]) [Perkin-Elmer Cetus, 
Norwalk, CT]. The downstream and the upstream primers (.15 µM each) [Clontech, 
Palo Alto, CA] were next added to each sample, the tubes microfuged, and then 
incubated in a thermocyler (MJ Research Inc., Watertown, MA), using the following 
program: 
(A) INITIAL DENATURATION -- 95 °C for 6 Min. 
(B) SUBSEQUENT DENATURATION -- 95 °C for 30 Sec. 
(C) ANNEALING OF PRIMERS -- 55 °C for 30 Sec. 
(D) EXTENSION OF PRIMERS -- 72 °C for 30 Sec. 
(E) REPEAT STEPS B-D -- 30 cycles 
After amplification, the amplified PCR products were extracted using 100 µL of a 
chloroform:isoamyl alcohol (24: 1) solution (Sigma Chemical Co., St. Louis, MO). 
BCL-2 Vector 
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A bluescript (SK, M13) vector (a kind gift of Dr. Michael Cleary, Stanford 
University Medical Center, Stanford, CA), which contains an 850 basepair (bp) open 
reading frame (ORF) from the BCL-2 oncogene was used as a positive control for the 
reverse transcription and Polymerase Chain Reaction (rtPCR). 
Restriction Endonuclease Di&ests 
10 µL of amplified PCR product (see above) was added to 1 µL (10 U) of Mbol 
restriction endonuclease (Gibco/BRL, Grand Island, NY), 2 µL of lOX reaction buffer 
(Gibco/BRL), and 7 µL of H20. This mixture was then incubated overnight at 37 °C. 
Polyacrylamide Gel Electrophoresis (PAGE) 
rtPCR products and restriction endonuclease digests were examined by 12 % 
PAGE, in accordance with a standard procedure (Sambrook et al., 1989); DNA was 
stained with .5 µg/mL ethidium bromide (Sigma Chemical Co., St. Louis, MO), and was 
then visualized under an ultraviolet transilluminator. 
Calcium Ionophore 
The calcium ionophore which was used in this project is A23187. It was 
purchased commercially (Calbiochem, San Diego, CA), and was used at a final 
concentration of 4 µM. 
CHAPTER ID 
RESULTS 
aTCR Monoclonal Antibody Induces Apoptosis in SUP-T13 Cells 
SUP-T13 cells were treated, in triplicate for three days, with either 50 µglmL of 
cxTCR monoclonal antibody (mAb), 50 µglmL of cxTCR mAb plus 50 µglmL of cxCD3 
mAb, or were left untreated (medium control). Cell viabilities, as determined by trypan 
blue-exclusion, were determined once a day for each treatment group. Previous work 
(Takahashi et al., 1989) has shown that SUP-T13 cell death induced by cxTCR mAb and 
other agents, such as calcium ionophores and -y-irradiation, occurs via apoptosis. 
Therefore, cell viability was used throughout this investigation as an indirect measure of 
apoptosis. 
With comparison to the medium control, SUP-T13 cells undergo apoptosis in 
response to treatment with the cxTCR mAb (Figure 1). Cell viability starts to decrease 
after Day 1, and it reaches its lowest point after Day 3 (76%). These results also show 
a difference of -20% in percent viability between the cxTCR mAb treated-SUP-TB cells 
and the medium control. The cxCD3 mAb, when administered simultaneously with the 
cxTCR mAb, prevents apoptosis. Furthermore, this rescue from apoptosis is very 
complete, as evidenced by the disappearance of the aforementioned difference in percent 
viability, with SUP-T13 cell viabilities being nearly equivalent to those of the medium 
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control ( -90%) on all three days. Some cell death ( -5%) occurred in the medium 
control. This death can be attributed to either physical injury, old-age, overcrowding, 
or spontaneous apoptosis. 
Neither SUP-T13 Variant Undera=oes aTCR-Mediated Apoptosis 
Both of the variant cell lines, SUP-T13 Clone A3 and SUP-T13 Clone C8, were 
treated, in triplicate for three days, with either 50 µglmL of aTCR mAb, 50 µglmL of 
aTCR mAb plus 50 µglmL of aCD3 mAb, or were left untreated (medium control). 
Cell viabilities, as determined by trypan blue-exclusion, were taken once a day for each 
treatment group. As can be seen in Figures 2 and 3, neither of the SUP-T13 variant cell 
lines undergoes apoptosis upon treatment with the aTCR mAb. Both of the variants 
show killing curves for the aTCR mAb-treated cells which paralleled those of the 
medium control for all three days, with cell viabilities being approximately equivalent 
(88%-94% for Clone A3 and 78-85% for Clone C8). Since no apoptosis was induced 
with the aTCR mAb, there was no opportunity for the aCD3 mAb to exert its rescue 
effect(s) when administered simultaneously with the aTCR mAb. Again, some of the 
cells in the medium control died, either due to physical injury, old-age, overcrowding, 
or spontaneous apoptosis. 
SUP-T13 Cells Express BCL-2 mRNA 
To determine whether SUP-T13 cells expressed BCL-2 mRNA, reverse 
transcription and Polymerase Chain Reaction (rtPCR) were performed. Figure 4 shows 
the results of Polyacrylamide Gel Electrophoresis (PAGE) of rtPCR products of extracted 
25 
SUP-T13 RNA. 
The first two lanes of the gel represent the negative and positive controls, 
respectively, for the rtPCR assay. rtPCR was either performed in the absence of SUP-
T13 RNA (Lane 1) or on SUP-T13 RNA using primers for a constitutively transcribed 
gene, Histone 3.3. No bands could be detected in Lane 1, indicating that there was no 
non-specific amplification during the rtPCR reaction. A band of the expected size of 
~ 230 basepairs (bp) was detected in Lane 2, indicating that the rtPCR reaction 
proceeded properly. 
Lanes 3 and 4 both represent BCL-2 amplification products. Lane 3 serves as a 
positive control for BCL-2, since rtPCR, using primers for BCL-2, was performed on 
a bluescript (SK, M13-) vector which contained a BCL-2 DNA insert. The amplification 
product obtained was ~ 319 bp in size, as expected with the primers used. Lane 4 
represents the rtPCR amplification product, again in the presence of primers for BCL-2, 
which was obtained using RNA extracted from SUP-T13 RNA. A band of ~319 bp was 
obtained, comparable to that in Lane 3, indicating that SUP-T13 cells express BCL-2 
mRNA. 
To further confirm that these amplification products contained BCL-2 sequences, 
restriction endonuclease digests, using Mbol, were performed on them. A single Mbol 
restriction site is present in the 319 bp region that is flanked by the BCL-2 primers. As 
a result, two restriction-digest products of ~ 260 bp and ~ 60 bp are obtained. Lane 5 
shows the results from the Mbol digestion of the bluescript (SK, M13-) amplification 
product, and Lane 6 shows the results from the Mbol digestion of the SUP-T13 
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amplification product. The - 260 bp band is clearly evident in both lanes; the smaller 
-60 bp band was not detectable, probably because it bound less Ethidium Bromide. 
These results further confirm that the rtPCR products obtained are from a region of BCL-
2 and that SUP-T13 cells express BCL-2 mRNA. 
Parental SUP-T13 and Both Clone A3 and Clone CS Cells Express Moderate 
Amounts of Endo&enous BCL-2 
Endogenous BCL-2 oncoprotein levels in SUP-T 13 cells were next compared to 
those of the two variants, SUP-T13 Clone A3 and Clone CS. 1 x ID6 of each cell type 
was harvested, in triplicate, and stained for flow cytometry analysis of endogenous BCL-
2 levels. 
As can be seen in Figure 5, both the parental SUP-T13 cells and the two SUP-
T13 variants, Clone A3 and Clone CS, possess endogenous BCL-2 oncoprotein levels. 
The results also show that the endogenous levels of BCL-2 are approximately equivalent 
between the parental SUP-T13 and the variant Clone CS. However, variant Clone A3 
possesses slightly lower levels of endogenous BCL-2 oncoprotein than either of these two 
cell lines. Furthermore, our laboratory compared these levels to those of peripheral 
blood lymphocytes (PBLs), which express little or no BCL-2, and to those of a high 
BCL-2-expressing cell line (EBNA 293). As can also be seen from Figure 5, the SUP-
T13 cells and the variants possess moderate amounts of endogenous BCL-2 oncoprotein, 
since their levels fall mid-way between the PBLs and the EBNA 293 cells. An analysis 
of variance was performed, followed by a Tukey test, in order to determine the statistical 
significance of these endogenous BCL-2 levels. The results showed that the differences 
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seen in BCL-2 oncoprotein levels in PBLs, Clone A3, and EBNA 293 were statistically 
significantly different from those of SUP-T13 and Clone C8 (p < .001). 
Histo,:rams Indicate Consistency and Sensitivity of Flow Cytometry 
To address the issue of whether flow cytometry is a consistent and sensitive 
means for detecting changes in BCL-2 oncoprotein levels in SUP-T13 cells, an 
experiment (one timepoint) was performed with two apoptosis-inducing agents. 1 x 1()6 
SUP-T13 cells were placed in 1 mL of RPMI medium, and were treated with either 50 
µL of aTCR mAb or 4 µM of the calcium ionophore, A23187. The cells were incubated 
at 37 °C for 1 Hr., and were then analyzed by flow cytometry. 
Panel A of Figure 6 shows the results for the O Hr., 1 Hr. aTCR mAb, and 1 Hr. 
aTCR mAb plus aCD3 mAb treatments of SUP-T13 cells. The histograms within each 
triplicate display tight constancy, indicating that the technique is very reproducible. 
Furthermore, there is congruency between the three treatment groups, indicating that 
BCL-2 oncoprotein levels are not changing with either those treatments which induce 
apoptosis, or with those which rescue it. Panel B of Figure 6 shows the results of the 
0 Hr. and the 1 Hr. treatment of SUP-T13 cells with the calcium ionophore, A23187. 
As was seen above, there is tight constancy within each triplicate. However, there is a 
lack of congruency between the two treatment groups, as the SUP-T13 cells which were 
treated with A23187 for 1 Hr. display a sub-population of BCL-21ow cells. This sub-
population was seen consistently in each histogram, and it accounted for ~ 25 % of the 
total cells. In each other treatment group of Figure 6, this BCL-21ow sub-population never 
exceeded more than 4 % of the total cells. These data show that flow cytometry can 
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detect changes in BCL-2 oncoprotein levels within a small population ( - 25 % ) of cells. 
More importantly, - 25 % of SUP-T 13 cells underwent apoptosis when treated with the 
aTCR mAb (see Figure 1). Therefore, even if this small number of apoptotic cells were 
losing BCL-2 expression, flow cytometry would have been able to detect this change. 
BCL-2 Expression does not Chan1:e in SUP-T13 Cells Over Time 
To further determine whether BCL-2 expression changes with aTCR mAb 
treatment, kinetic studies of BCL-2 expression were carried out. 1 x 106 SUP-T13 cells 
were placed in 1 mL of RPMI medium and were treated, in triplicate, with either no 
mAb (medium control), with 50 µg/mL of aTCR mAb, or with 50 µg/mL of aTCR mAb 
plus 50 µg/mL of aCD3 mAb. The cells were then incubated at 37 °C for one, two, 
four, or eight hours, at which times they were harvested. These timepoints were chosen 
according to the literature on BCL-2, which showed that the majority of BCL-2 de-
regulation occurs before twelve hours (Deng et al., 1993; Cuende et al., 1993; and 
Makover et al., 1993) after apoptosis induction. Using flow cytometry, BCL-2 
oncoprotein levels were measured for each timepoint. BCL-2 expression was denoted 
as a proportion of the means from the experimental treatments to those of the medium 
control, with the medium control being 1. Parallel cell viability experiments were also 
performed, once a day for three days and with identical mAb treatments, in order to 
confirm that the mAbs were exerting their expected results. 
As can be seen in Figure 7, BCL-2 expression levels, regardless of treatment 
group, remained relatively constant throughout the duration of the eight-hour treatment 
period. Also, the curve of those cells which were treated with the aTCR mAb parallels 
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the curve of those cells which were treated with both the aTCR mAb plus the aCD3 
mAb, further indicating that BCL-2 expression is not induced in one group relative to the 
other. 
BCL-2 Expression does not Chana=e in the SUP-T13 Variants Over Time 
Similar kinetic studies were also performed on the two SUP-T13 variants, Clone 
A3 and Clone CS. 1 x lff of each of SUP-T13 variant cell line, Clone A3 and Clone 
CS, were placed in 1 mL of RPMI medium and were either treated, in triplicate, with 
no mAb (medium control), with 50 µg/mL of aTCR mAb, or with 50 µg/mL of aTCR 
mAb plus 50 µg/mL of aCD3 mAb. The cells were then incubated at 37 °C for one, 
two, four, or eight hours, at which times they were harvested. Using flow cytometry, 
BCL-2 oncoprotein levels were measured for each timepoint. BCL-2 expression was 
denoted as a proportion of the means from the experimental treatments to those of the 
medium control, with the medium control being 1. Parallel cell viability experiments 
were performed for each variant, once a day for three days and with identical mAb 
treatments, in order to confirm that the mAbs were exerting their expected effects. 
As can be seen in Figures S and 9, BCL-2 expression levels remained constant, 
for both SUP-T13 Clone A3 and SUP-T13 Clone CS, throughout the duration of the 
eight-hour treatment period. The curve of those cells which were treated with the aTCR 
mAb closely parallels the curve of those cells which were treated with both the aTCR 
mAb and the aCD3 mAb. Thus, BCL-2 levels do not change in response to either the 
aTCR mAb or the aCD3 mAb treatments in either the parental or variant SUP-T13 cells. 
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The aBCL-2 m.Ab is Specific for the BCL-2 Oncoprotein 
To verify that the aBCL-2 mAb used in the flow cytometry studies was in fact 
specific for the BCL-2 oncoprotein, an immunoblotting experiment was performed. 
Figure 10 shows the results of immunoblotting in which 1 x 1()6 SUP-T13 cells were 
treated with either 50 µg/mL of aTCR mAb for 4 Hr. (Lane 4) or were cultured in 
medium for 4 Hr. (Lanes 1-3). The medium control was performed in triplicate in order 
to determine the consistency of the assay. The cells were lysed in Triton-X lysis buffer 
and the lysates were run on a 15 % polyacrylamide gel, in accordance with a standard 
procedure (Laemmli, 1970 and Sambrook et al., 1989). The proteins were subsequently 
electroblotted onto an Immobilon PVDF membrane and stained with the aBCL-2 mAb, 
followed by affinity-purified goat anti-mouse/horseradish peroxidase-conjugated 
antiserum. Finally, the reaction was visualized with a solution of DAB and hydrogen 
peroxide. 
As can be seen in Figure 10, a single, sharp band of - 25 kD (the apparent 
molecular weight of the BCL-2 oncoprotein) appears in all four lanes, indicating that the 
aBCL-2 mAb carries extremely high specificity for the BCL-2 oncoprotein. The 
equivalent intensity of the bands, furthermore, indicates that the BCL-2 oncoprotein 
levels remained unchanged between the aTCR mAb-treated SUP-T13 cells (Lane 4) and 
the untreated SUP-T13 cells (Lanes 1-3). In addition, the internal consistency of the 
assay was confirmed by the equivalent intensity of the bands in Lanes 1-3, which 
represent three independent samples of untreated SUP-T13 cells. This corroborates the 
flow cytometry data, which showed constancy in BCL-2 oncoprotein levels during the 
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various mAb treatments of SUP-T13 cells (Figure 9), and it reinforces the fact that BCL-
2 oncoprotein levels remain unchanged in SUP-Tl3 cells, regardless of mAb 
treatment. 
aCD3 mAb does not Rescue Other Forms of Apoptosis in SUP-T13 Cells 
Since the aCD3 mAb rescues aTCR-mediated apoptosis in SUP-T13 cells, 
experiments were performed in order to determine whether the aCD3 mAb could rescue 
two alternative forms of apoptosis, namely those which are induced by an aF AS mAb 
and by calcium ionophores. 1 x 1()6 SUP-T13 cells were treated, in triplicate for three 
days, with either 4 µM of calcium ionophore, 4 µM of calcium ionophore plus 50 µglmL 
of aCD3 mAb, 5 µglmL of aFAS mAb, 5 µglmL of aFAS mAb plus 50 µglmL of 
aCD3 mAb, or were left untreated (medium control). Cell viabilities, as determined by 
trypan blue-exclusion, were determined once a day for each treatment group. 
As can be seen in Figures 11 and 12, with comparison to the medium control, 
both the aF AS mAb and the calcium ionophore, respectively, appeared to induce severe 
apoptosis in SUP-T13 cells, with cell viabilities approaching zero after three days. 
Furthermore, neither the calcium ionophore-induced apoptosis nor the aFAS mAb-
induced apoptosis was reversed by the aCD3 mAb. These data indicate that multiple 
pathways to apoptosis may exist in SUP-T13 cells or, at least, that the aCD3 mAb exerts 
its effects prior to the merging of such pathways. 
Summary of Results 
Initially, SUP-T13 cells were treated, for three days, with either aTCR mAb, 
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aTCR mAb plus aCD3 mAb, or were left untreated, as a medium control. As was 
previously described by Takahashi et al. (1989), treatment of SUP-T13 cells with the 
aTCR mAb induced apoptosis, as measured by cell viability (Figure 1). Simultaneous 
treatment with an aCD3 mAb, on the other hand, reversed this apoptosis. Furthermore, 
this reversal was complete, with the aCD3 mAb-treated SUP-T13 cells displaying 
viabilities which paralleled those of the untreated medium control (Figure 1). Both of 
the SUP-T13 variant clones, Clone A3 and Clone CS, possess TCR/CD3 complexes on 
their cell surface (data not shown). Despite this fact, however, neither of these two 
variants underwent apoptosis upon treatment with the aTCR mAb (Figures 2 and 3, 
respectively). 
These data clearly suggest that there exists a mechanism(s) for protecting SUP-
T13 cells from apoptosis, regardless of whether this protection is conferred by the aCD3 
mAb treatment, as was seen in the parental SUP-T13 cells, or by some endogenous 
factor(s) present within the cell, as was seen in both of the variants. One entity which 
has been shown to be a potent suppressor of apoptosis is the BCL-2 oncogene (Cuende 
et al., 1993; reviewed by Gerchenson et al., 1992; reviewed by Korsmeyer, 1992; Lee 
et al., 1993; and Weiss et al., 1987). As a result, this investigation was instigated in 
order to determine whether a relationship exists between BCL-2 oncogene expression 
levels and the induction of apoptosis in SUP-T13 cells. 
The next logical phase of the investigation was to determine whether SUP-Tl3 
cells even express the BCL-2 oncogene. This was accomplished by rtPCR and PAGE, 
along with further confirmation by restriction endonuclease digests of the rtPCR 
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products. Using primers specific for a -319 bp region of the BCL-2 oncogene, rtPCR 
amplification results showed that SUP-T13 cells possessed detectable endogenous levels 
of BCL-2 mRNA (Figure 4). Restriction endonuclease digestion of these same rtPCR 
products yielded a restriction fragment of the correct size, further indicating that the 
rtPCR amplification was specific for BCL-2 and, consequently, the endogenous presence 
of BCL-2 mRNA in SUP-T13 cells. 
With data supporting that SUP-T13 cells do express BCL-2 mRNA, the next 
phase of the project was centered on determining the relative amounts of endogenous 
BCL-2 oncoprotein possessed by the parental SUP-T13 cells and the two SUP-T13 
variants, Clone A3 and Clone C8, and whether those levels changed over several 
timepoints. This was accomplished using an internal-staining protocol for flow 
cytometry, which measures BCL-2 oncoprotein levels directly. SUP-T13 cells were 
treated for either O Hr., 1 Hr., 2 Hr., 4 Hr., or 8 Hr. with aTCR mAb or aTCR mAb 
plus aCD3 mAb. As can be seen in Figure 5, both the parental SUP-T13 cells and the 
two SUP-T13 variants, Clone A3 and Clone C8, possessed nearly identical amounts of 
endogenous BCL-2 oncoprotein. Furthermore, as was determined by our laboratory, 
these levels represent moderate amounts of BCL-2 oncoprotein, when compared to the 
low-BCL-2-expressing PBLs and the high-BCL-2-expressing EBNA 293 cells (Henderson 
et al., 1991 and Reed, 1994). 
With the establishment of the consistency of flow cytometry, along with the 
demonstration that it can discriminate sub-populations of BCL-2-expressing SUP-T13 
cells (Panels A and B, respectively, Figure 6), experiments were performed to determine 
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whether BCL-2 expression could be induced or repressed with the various mAb 
treatments for either O Hr., 1 Hr., 2 Hr., 4 Hr., or 8 Hr. Figure 7 shows that BCL-2 
oncoprotein levels remained relatively constant in SUP-T13 cells, regardless of whether 
they were treated with the aTCR mAb alone or with a combination of aTCR mAb plus 
aCD3 mAb. These data contradict the most likely prediction of H-1, which states that 
BCL-2 oncogene expression levels are expected to increase during the aCD3 mAb 
treatment, since it reverses the aTCR mAb-induced apoptosis. Neither of the two SUP-
T13 variants, Clone A3 and Clone C8, shows any changes in BCL-2 oncoprotein 
expression levels during either the aTCR mAb or the combination aTCR mAb plus 
aCD3 mAb treatments (Figures 8 and 9, respectively). Again, this contradicts the most 
likely prediction of H-1 because elevated BCL-2 levels would be expected in these cells, 
especially during the aTCR mAb treatments, since these cells do not undergo apoptosis 
with this treatment. These data clearly show that changes in BCL-2 expression are not 
necessary for either the induction or prevention of apoptosis in SUP-T13 cells. This 
suggests, but does not prove, that the aTCR mAb-mediated apoptosis in SUP-T13 cells 
is BCL-2-independent. 
To further confirm the flow cytometry data, immunoblotting was performed for 
two reasons. First, it would give information about the specificity of the aBCL-2 mAb 
and show whether it cross-reacts with other proteins. Second, it would be a good way 
of confirming that BCL-2 oncoprotein levels do not change during the various mAb 
treatments. Since only parental SUP-T13 cells undergo apoptosis upon treatment with 
the aTCR mAb, immunoblotting was performed only on these cells, using a negative 
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control (0 Hr.) and a later timepoint ( 4 Hr.) of treatment. As can be seen from Figure 
10, the aBCL-2 mAb exhibits extremely high specificity for the ~ 25 kD BCL-2 
oncoprotein, with no apparent hybridization to proteins of other sizes. Furthermore, the 
intensity of the bands is equivalent in both the O Hr. and the 4 Hr. aTCR mAb 
treatments, indicating that BCL-2 oncoprotein levels remained unchanged between the 
two timepoints. The equal intensity of the bands also indicates that the assay yielded 
consistent and reproducible results. These data are consistent with the flow cytometry 
data on SUP-T13 cells, which also showed no substantial changes in BCL-2 oncoprotein 
levels during the various mAb treatments (Figure 7). 
Two alternative means of inducing apoptosis in SUP-T13 cells are by the use of 
calcium ionophores (Takahashi et al., 1989) and by treatment with an aFAS mAb 
(Takahashi et al., 1993). To determine the effect of the aCD3 mAb on apoptosis 
induced by these agents, SUP-T13 cells were treated, for three days, with either a 
calcium ionophore or with aFAS mAb, both with and without the aCD3 mAb. As can 
be seen from Figures 11 and 12, the aCD3 mAb exerted no rescue effects on either the 
aFAS mAb-treated or the calcium ionophore-treated SUP-T13 cells, respectively. The 
aCD3 mAb-treated cells displayed similar killing curves to those cells in the 
experimental treatment group, with the cell viabilities decreasing to near zero. These 
data suggest that multiple pathways to apoptosis exist in SUP-Tl3 cells, or that a single 
pathway has divergent proximal branches, thereby being under the control of multiple 
agents. In this case, the aCD3 mAb exerts its anti-apoptotic effects on only one of these 
proximal branches (e.g., the branch which is triggered by the aTCR mAb signal). 
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Fiwre 1. aTCR mAb Treatment of SUP-T13 Cells. 
This graph represents killing curves of 1 x 1()6 SUP-T13 cells which were either 
treated with 50 µglmL of aTCR mAb ( ■), 50 µglmL of aTCR mAb plus 50 µglmL of 
aCD3 mAb (•), or were left untreated, serving as the medium control (x). All 
treatments were carried out for three days and in triplicate. Cell viability, as assessed 
by trypan blue-exclusion, was determined once a day. Error bars indicate +/- one 
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Fi&Qre 2. aTCR mAb Treatment of SUP-T13 Variant Clone A3 Cells. 
This graph represents killing curves of 1 x 1()6 SUP-T13 variant Clone A3 cells 
which were either treated with 50 µglmL of aTCR mAb ( ■), 50 µglmL of aTCR mAb 
plus 50 µglmL of aCD3 mAb ( • ), or were left untreated, serving as the medium control 
(x). All treatments were carried out for three days and in triplicate. Cell viability, as 
assessed by trypan blue-exclusion, was determined once a day. Error bars indicate +/-
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Fi&Qre 3. aTCR mAb Treatment of SUP-T13 Variant Clone C8 Cells. 
This graph represents killing curves of 1 x 1()6 SUP-T13 variant Clone C8 cells 
which were either treated with 50 µglmL of aTCR mAb ( ■), 50 µglmL of aTCR mAb 
plus 50 µglmL of aCD3 mAb (•), or were left untreated, serving as the medium control 
(x). All treatments were carried out for three days and in triplicate. Cell viability, as 
assessed by trypan blue-exclusion, was determined once a day. Error bars indicate +/-
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Fi&qre 4. rtPCR of SUP-T13 RNA and Mbol Digests of rtPCR Amplification 
Products. 
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This photograph shows the results from rtPCR of SUP-T13 RNA and Mbol 
restriction endonuclease digests of rtPCR products. Lane 1 represents the negative 
control in which rtPCR was performed in the absence of input RNA. Lane 2 represents 
the positive control in which rtPCR was performed on SUP-T13 RNA with primers for 
Histone 3.3. Lanes 3 and 4 represent BCL-2 amplification products (see arrowhead) 
from either a bluescript (SK, M13-) vector containing a BCL-2 DNA insert or from SUP-
T13 RNA, respectively. Lanes 5 and 6 represent Mbol restriction endonuclease digests 
of rtPCR products from Lanes 3 and 4, respectively. Mspl digests of pGEM-3Z DNA 
served as molecular weight standards, and are shown on the right. 
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Fi&Yre 5. Comparison of Endogenous BCL-2 Levels Between Parental and Variant SUP-
T13 Cells Versus PBLs and EBNA 293. 
This graph represents 1 x 1()6 of each cell type which was harvested, in triplicate 
and without any mAb treatment, and then internally stained with an aBCL-2/FITC mAb 
and fixed. The cells were analyzed on a flow cytometer and BCL-2 oncoprotein levels 
were expressed as a ratio of the means of each cell type, normalized to the level of 
staining of parental SUP-T13 cells (equal to 1). Error bars indicate +/- one standard 
deviation from the mean for each cell type. Following an analysis of variance, along 
with a Tukey test, those groups of cells which had significantly different levels of 
endogenous BCL-2 oncoprotein levels were denoted by a star(*) [p < .001]. 
~ 
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Fi&0re 6. Consistency and Sensitivity of Flow Cytometry for Detecting Changes in 
BCL-2 Oncoprotein Levels. 
46 
This figure shows the actual flow cytometry histograms of each triplicate for two 
different treatment groups of SUP-T13 cells. In one treatment group, 1 x 1()6 SUP-T13 
cells were placed in 1 mL of RPMI medium and treated with either no mAb (0 Hr.), 50 
µg/mL of cxTCR mAb for 1 Hr, or 50 µg/mL of cxTCR mAb plus 50 µg/mL of cxCD3 
mAb for 1 Hr. (Panel A). In the second treatment group, 1 x 1()6 SUP-T13 cells were 
placed in 1 mL of RPMI medium and treated with either no A23187 (0 Hr.), or with 4 
µM 'Of A23187 for 1 Hr. (Panel B) The y-axis represents the number of cells, and the 
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Fieure 7. BCL-2 Expression During Eight Hours of mAb Treatment in SUP-T13 Cells. 
This graph represents 1 x 1()6 SUP-T13 cells which were either treated, in 
triplicate, with 50 µglmL of aTCR mAb ( ■), 50 µglmL of aTCR mAb plus 50 µglmL 
of o:CD3 mAb ("' ), or were left untreated, serving as the medium control. After the 
appropriate timepoint, the cells were harvested and internally stained with an aBCL-2-
FITC mAb and fixed. The cells were then analyzed on a flow cytometer and BCL-2 
oncoprotein levels were expressed as a ratio of the means from the two experimental 
groups to the mean of the medium control, with the medium control being depicted as 
1. Error bars indicate + /- one standard deviation from the mean for each treatment 
group. 
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Fiwre 8. BCL-2 Expression During Eight Hours of mAb Treatment in SUP-T13 
Variant Clone A3 Cells. 
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This graph represents 1 x 1()6 SUP-T13 Variant Clone A3 cells which were either 
treated, in triplicate, with 50 µg/mL of offCR mAb ( ■), 50 µglmL of aTCR mAb plus 
50 µg/mL of aCD3 mAb ( • ), or were left untreated, serving as the medium control. 
After the appropriate timepoint, the cells were harvested and internally stained with an 
aBCL-2-FITC mAb and fixed. The cells were then analyzed on a flow cytometer and 
BCL-2 oncoprotein levels were expressed as a ratio of the means from the two 
experimental groups to the mean of the medium control, with the medium control being 
depicted as 1. Error bars indicate + /- one standard deviation from the mean for each 
treatment group. 
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Fi&nre 9. BCL-2 Expression During Eight Hours of mAb Treatment in SUP-T13 
Variant Clone CS Cells. 
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This graph represents 1 x 106 SUP-T13 Variant Clone CS cells which were either 
treated, in triplicate, with 50 µg/mL of aTCR mAb (■), 50 µglmL of aTCR mAb plus 
50 µglmL of aCD3 mAb (•), or were left untreated, serving as the medium control. 
After the appropriate timepoint, the cells were harvested and internally stained with an 
aBCL-2-FITC mAb and fixed. The cells were then analyzed on a flow cytometer and 
BCL-2 oncoprotein levels were expressed as a ratio of the means from the two 
experimental groups to the mean of the medium control, with the medium control being 
depicted as 1. Error bars indicate + /- one standard deviation from the mean for each 
treatment group. 
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Fiarnre 10. Immunoblotting of aTCR mAb-Treated SUP-T13 Cells. 
This photograph represents immunoblotting of 1 x 1()6 SUP-T13 cells which were 
either treated with 50 µg/mL of aTCR mAb for 4 Hr (Lane 4) or were left untreated 
(Lanes 1-3). The cells were lysed in Triton-X lysis buffer and electroblotted onto an 
Immobilon membrane. The membrane was next stained with aBCL-2 mAb, followed 
by affinity-purified goat anti-mouse/horseradish peroxidase-conjugated antiserum. 
Finally, the reaction was visualized with a solution of DAB and hydrogen peroxide. 
Low-molecular weight markers (ovalbumin [45 kD], pepsin [34.7 kD], trypsinogen [24 
kD], {j-lactoglobin [18.4 kD], and lysozyme [14.3 kD]) served as standards, and they are 
indicated on the left. 
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Fiamre 11. aFAS mAb Treatment of SUP-T13 Cells. 
This graph represents killing curves of 1 x 1()6 SUP-T13 cells which were either 
treated with 5 µglmL of aFAS mAb (o), 5 µglmL of aFAS mAb plus 50 µg/mL of 
aCD3 mAb (A), or were left untreated, serving as the medium control ( ■). All 
treatments were carried out for three days and in triplicate. Cell viability, as assessed 
by trypan blue-exclusion, was determined once a day. Error bars indicate +/- one 










Fi&Jire 12. Calcium Ionophore Treatment of SUP-T13 Cells. 
This graph represents killing curves of 1 x 1()6 SUP-T13 cells which were either 
treated with 4 µM of calcium ionophore (o), 4 µM of calcium ionophore plus 50 µg/mL 
of aCD3 mAb (t.), or were left untreated, serving as the medium control ( ■). All 
treatments were carried out for three days and in triplicate. Cell viability, as assessed 
by trypan blue-exclusion, was determined once a day. Error bars indicate +/- one 
standard deviation from the mean for each treatment group. 
CALCIUM IONOPHORE KILLING 
OF SUP-T13 








0 1 2 3 
DAY 
( -a- MEDIUM ~ IONOPHORE -6. IONO/aCD3 ) 
59 
Si&nificance of Results 
CHAPTER IV 
DISCUSSION 
The findings from the investigation indicate that there is no relationship between 
increased BCL-2 expression levels and the cxCD3 mAb-mediated rescue of the cxTCR 
mAb-induced SUP-T13 apoptosis. This finding initially appeared peculiar, especially 
because of what was reported in early studies about the anti-apoptotic effects of the BCL-
2 oncoprotein, both in vitro and in vivo, in other model systems. Nevertheless, this 
finding suggests that BCL-2-independent pathways for blocking apoptosis in T cells may 
exist. This is in accord with several recent investigations pertaining to BCL-2 and 
apoptosis in lymphoid cells. 
Nufiez et al. (1990) studied the effects of BCL-2 overexpression in FL5.12, a B 
cell line whose viability is dependent on interleukin-3 (IL-3), and in CTLL-2 cells, a T 
cell line whose viability is dependent on interleukin-2 (IL-2). Ordinarily, both of these 
cell lines enter apoptosis upon withdrawal of their respective interleukin growth factor. 
The results showed that overexpression of BCL-2 in FL5.12 cells did confer a survival 
advantage, even 72 hours after IL-3 withdrawal--atypical of malnourished cells. On the 
other hand, BCL-2 overexpression in CTLL-2 cells did not confer a survival advantage, 
since the majority of the cells underwent apoptosis 24-72 hours after IL-2 withdrawal--
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typical of malnourished cells. These results indicate that the anti-apoptotic effects of 
BCL-2 are not universal and that they may be dependent on cell-type and/or on growth 
factor-requirement restrictions. Thus, it is reasonable to postulate that SUP-T13 cells 
represent a T cell type in which apoptosis-inhibition does not depend on pathways which 
utilize the BCL-2 oncogene. 
Weller et al. (1994) also performed an investigation on CTLL-2 T cells. They 
examined BCL-2 mRNA levels during apoptosis which was induced by either IL-2 
withdrawal or by treatment with transforming growth factor-# (TGF#), a potent 
immunosuppressive cytokine which induces apoptosis in T cells. Their results showed 
decreases in BCL-2 mRNA levels in the CTLL-2 cells during the IL-2 withdrawal, but 
no changes during the TGF# treatments. These results suggest that withdrawal of IL-2 
leads to lower BCL-2 expression, which allows apoptosis to occur. This interpretation 
would seem to contradict the results of Nunez et al. (1990). Both results are 
interpretable if BCL-2 is not involved in controlling the apoptosis pathway induced by 
IL-2 withdrawal. Therefore, correlations of BCL-2 mRNA levels with other events are 
not causal. 
Cuende et al. (1993) performed an investigation focusing on apoptosis in an 
immature B cell line, called WEHI-231. They showed that engagement of the membrane 
IgM (mlgM) receptor with an algM mAb induced apoptosis in WEHI-231 cells, along 
with down-regulation of BCL-2 mRNA. Transfection of a BCL-2 construct into WEHI-
231 cells, though, did not confer resistance to the algM mAb-induced apoptosis. It did, 
however, render these cells less susceptible to apoptosis induced by heat-shock. These 
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results indicate that both BCL-2-dependent and BCL-2-independent mechanisms for the 
blockage of apoptosis can exist even in a given cell lineage. 
From the data of this investigation and that of Cuende et al. (1993), it is 
reasonable to speculate that BCL-2 may not be involved in rescuing those forms of 
apoptosis which are triggered by signalling through an antigen receptor, as occurs during 
algM mAb treatment of B cells or during the aTCR mAb treatment of SUP-Tl3 cells. 
This would further imply that BCL-2 may not have a role in the clonal deletion pathways 
involved in lymphocyte maturation and, therefore, is not necessary for thymic selection. 
In accordance with this, Sentman et al. (1991) developed a breed of transgenic mice 
called lclc"-BCL-2 which contained an insert of the human BCL-2 oncogene that was 
expressed only in the thymic cortex. co4+ cos+ thymocytes from these transgenic 
mice were found to be resistant to various forms of apoptosis. For example, the BCL-2 
transgene effectively blocked apoptosis which was induced by high doses of 
dexamethasone, a glucocorticoid. These CD4 + CDS+ thymocytes were also resistant to 
225 rads of ionizing radiation. Finally, these same thymocytes were resistant to 
apoptosis induced by an aCD3 mAb. These results from the lclc"-BCL-2 transgenic 
model strongly suggest that BCL-2 may act at a common decisional checkpoint in the 
glucocorticoid-, ionizing radiation-, and aCD3 mAb-induced apoptosis pathways. 
However, these researchers discovered that the majority of V/35, V/311, and V{317a+ (all 
autoreactive subsets of T cells) were not present in the peripheral circulation of the lclc"-
BCL-2 mice. These results strongly demonstrate that negative selection of autoreactive 
CD4 + cos+ thymocytes did occur, despite the fact that BCL-2 was overexpressed. As 
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in the aforementioned study, it can be concluded that both BCL-2-dependent and BCL-2-
independent mechanisms for the prevention of apoptosis exist in T cells. 
In view of the findings of Sentman et al. ( 1991), and assuming that SUP-T 13 cells 
represent immature thymocytes and that aTCR mAb treatment may be analogous to 
negative selection, it is thus not surprising that no changes in BCL-2 levels were seen 
during the mAb treatments. Although increased BCL-2 expression does not appear to 
be necessary for the negative selection of thymocytes, this is not necessarily an indication 
that it has no role whatsoever in the further development of thymocytes after thymic 
selection. BCL-2 may very well have a role in assuring the survival of mature 
thymocytes (e.g., after thymic selection has already occurred). 
To further clarify this issue, BCL-2 knock-out experiments have been performed. 
Nakayama et al. (1993) generated mice which were chimeric for a homozygous 
inactivation of the BCL-2 oncogene. These mice showed normal embryonic 
development, including the existence of phenotypically mature T cells in the peripheral 
circulation. These findings suggest that normal development of T cells does not require 
the BCL-2 oncogene. By four weeks of age, however, the percentage of these mature 
T cells dropped to near zero in the peripheral circulation, with cell death occurring via 
apoptosis. Furthermore, these mature T cells were susceptible to apoptosis induced by 
glucocorticoids, -y-irradiation, and aCD3 mAb--all of which is atypical of mature T cells. 
These results suggest that BCL-2 plays a significant role in prolonging the survival of 
mature T cells which have already undergone thymic selection. 
This theory is consistent with the data of Veis et al. (1993) which support a model 
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in which co4- cos- thymocyte precursor cells express high levels of BCL-2 oncoprotein 
and then lose this expression during thymocyte selection (e.g., the co4+ cos+ stage). 
If these cells are positively selected, however, and allowed to differentiate into fully 
mature CO4 + cos- or co4- cos+ T cells, BCL-2 oncogene expression is regained, thus 
allowing the survival of these cells for an impending immune response. 
The data from this investigation suggest that BCL-2 is not necessary for the aCO3 
mAb-mediated rescue of the aTCR mAb-induced apoptosis in SUP-T13 cells. Recent 
studies have suggested four other gene products as regulators of apoptosis. These are: 
C-MYC (Makover et al., 1991; Reed et al., 1990; and Shi et al., 1992), NUR-77 (Liu 
et al., 1994), BCL-X (Boise et al., 1993 and Korsmeyer et al., 1993), and BAX (Oltvai 
et al., 1993). 
For example, Hibner et al. (1993) compared algM mAb-induced apoptosis 
between parental WEHI-231 B cells and two variant lines, WEHI-231-Ml and WEHI-
231-M22. The WEHI-231 cells underwent apoptosis with the aigM mAb treatment, 
whereas neither of the two variants did, with BCL-2 mRNA levels being identical among 
all three cell lines. Conversely, the levels of another oncogene, C-MYC, whose 
expression has previously been shown to be involved in apoptosis, were found to be up-
regulated in both of the variants during the algM mAb treatments and strongly down-
regulated in the parental WEHI-231 cells. These results suggest that C-MYC up-
regulation, rather than BCL-2 up-regulation, may be sufficient to block apoptosis in 
certain lymphoid cells. This again points away from the view of BCL-2 as being the 
only suppressor of apoptosis. In light of these findings, it is possible that C-MYC up-
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regulation is responsible for either the aCD3 mAb-mediated rescue of apoptosis in SUP-
T13 cells or for the inherent resistance of SUP-T13 Clone A3 and Clone CS to this form 
of apoptosis. 
Liu et al. (1994) have described a gene which is involved in allowing ligand-
induced apoptosis to ensue in immature thymocytes The gene they studied, NUR-77, is 
a steroid receptor which acts as a zinc-finger transcription factor. In this study, NUR-77 
expression was found to be increased during apoptosis triggered by treatment with an 
aTCR mAb. Moreover, transfection of an antisense NUR-77 construct abrogated this 
apoptosis. These data thus describe another gene which can regulate cell death in 
lymphoid cells. Therefore, it is plausible to speculate that the aTCR mAb treatment of 
parental SUP-T13 cells increases NUR-77 expression thereby initiating apoptosis, via the 
transcription factor, whereas the aCD3 mAb treatment down-regulates NUR-77 
expression, allowing for survival of SUP-T13 cells. Likewise, the two SUP-T13 
variants, Clone A3 and Clone CS, may inherently possess defects in expression of the 
NUR-77 gene, resulting in its constitutive down-regulation. As a result, they are not 
prone to the aTCR mAb-induced apoptosis. 
BCL-X and BAX, two genes which have sequence homology with BCL-2, have 
been implicated in mediating apoptosis in lymphoid cells. Boise et al. (1993) have 
shown that two forms of BCL-X result from alternative splicing; one is BCL-XL and the 
other is BCL-X8 • These researchers stably transfected either a mock construct (the 
negative control), a BCL-XL construct, a BCL-X8 construct, a BCL-2 construct, a BCL-
XdBCL-2 construct, or a BCL-XsfBCL-2 construct into FL5.12 B cells, a cell line which 
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is ordinarily dependent upon IL-3 (Nunez et al., 1990). They showed increased survival 
times (up to 96 hours) of BCL-Xctransfected FL5.12 B cells after IL-3 deprivation, 
indicating that BCL-XL possesses anti-apoptotic properties. Furthermore, these survival 
times were twice as great as those of FL5.12 B cells transfected with BCL-2 only, 
showing that BCL-XL may be an even more potent inhibitor of apoptosis than BCL-2. 
Those cells that were doubly transfected with BCL-XL and BCL-2 did not show any 
better survival times than did the BCL-XL transfectants, indicating that there is no 
interaction between BCL-XL and BCL-2. The BCL-Xs transfected FL5.12 cells, on the 
other hand, died at the same rate upon IL-3 withdrawal as did the mock-transfected 
control cells, indicating that BCL-X8 has no rescue effects on apoptosis induced by 
growth· factor withdrawal. However, in those FL5.Bl2 B cells which were doubly 
transfected with BCL-X8 and BCL-2, BCL-X8 negated the previously seen anti-apoptotic 
effects of BCL-2, because those cells also died at a rate comparable to the control 
transfectants. This result indicates that BCL-X8 may play a dominant role to BCL-2 in 
the regulation of apoptosis. Therefore, it is possible that the BCL-X proteins may have 
a greater role in apoptosis induction in parental SUP-T13 cells than does the BCL-2 
oncoprotein. It is conceivable that BCL-Xs levels are up-regulated and BCL-XL levels 
are either unaffected or down-regulated during the aTCR mAb treatments. Conversely, 
BCL-XL expression may greatly increase, while BCL-X8 levels are down-regulated or 
unaffected, during the aCD3 mAb-mediated rescue of the apoptosis induced by the 
aTCR mAb. This theory would explain the fact that BCL-2 levels remained unchanged 
during the various mAb treatments. In view of the two SUP-T13 variants, Clone A3 and 
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Clone CS, two possibilities are likely. One, it is reasonable to postulate that these cells 
possess some inherent defect which allows for the constitutive expression of BCL-XL. 
Two, it is equally reasonable to speculate that the two variants possess an inherent defect 
which causes a down-regulation of BCL-X8 • In either case, the end-result would be the 
same--the two SUP-T13 variants, Clone A3 and Clone CS, would be spared from the 
aTCR mAb-induced apoptosis. 
The work of Boise et al. (1993) also gave some indications about the role of 
BCL-X during thymocyte selection. They showed that immature CO4 + cos+ 
thymocytes expressed BCL-X but that freshly ·isolated, mature co4+ cos- or co4-
cos+ T cells did not. Furthermore, BCL-X8 is the predominant form of BCL-X which 
was found in these immature thymocytes. This may explain the results of Strasser et al. 
(1991), who demonstrated that BCL-2 overexpression did not perturb negative selection, 
therefore indicating that it occurred via a BCL-2-independent pathway. It is possible that 
regulation of BCL-X8 plays the dominant role in allowing (or blocking) apoptosis in 
thymocyte selection. Thus, autoreactive thymocytes may be triggered to undergo 
apoptosis via up-regulation of BCL-X8 expression. This finding can be extended to the 
SUP-T13 model of thymocyte selection, suggesting that BCL-X8 might be the key 
element which is involved in regulating apoptosis and selection of these analogues of 
immature thymocytes, thereby explaining the lack of BCL-2 involvement. 
Oltvai et al. (1993) have shown that BAX has the ability to dimerize with either 
itself or with BCL-2. They also investigated the IL-3-dependent B cell line, FL5.12 
(Nunez et al., 1990). FL5.12 B cells were either transfected with BAX or with a 
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combination of BAX and BCL-2. Those FL5.12 B cells which overexpressed BAX 
displayed increased susceptibility to apoptosis upon IL-3 withdrawal, with cell viabilities 
dropping to -20% after 30 hours. However, FL5.12 cells that were doubly-transfected 
with BAX and BCL-2 displayed increased survival times (-50%) 30 hours after IL-3 
withdrawal. These data suggest that excess BAX · may counteract the anti-apoptotic 
effects of BCL-2. Furthermore, the degree of apoptosis was directly proportional to the 
ratio of BAX to BCL-2, with its severity decreasing as this ratio decreased. From these 
data, the researchers postulated that BAX has the ability to homodimerize or to 
heterodimerize with BCL-2. If the former occurs, cells are rendered very susceptible to 
apoptosis; if the latter occurs, however, cells exhibit lower degrees of apoptosis. In 
SUP-T13 cells, it is possible that BAX levels are upregulated during the aTCR mAb 
treatments, . and the BAX homodimers could negate any anti-apoptotic effects of the 
endogenous BCL-2. In tum, this would result in the observed.entrance of the SUP-T13 
cells into apoptosis. The two SUP-T13 variants, Clone A3 and Clone CS, may have 
constitutively downregulated BAX activity. Consequently, no BAX homodimers can 
form, thereby conferring these cells inherent resistance to aTCR mAb-mediated 
apoptosis. 
Finally, recent evidence has accrued which shows that multiple pathways to 
apoptosis exist (Collins et al., 1993; Williams et al., 1993; and Wong et al., 1994). 
Schwartzman et al. (1993) have recently written a review about the biochemistry and 
molecular biology of apoptosis. With respect to thymocytes, they reiterate the fact that 
apoptosis can be induced by signalling through the TCR/CD3 complex or by treatments 
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with glucocorticoids, such as dexamethasone. They further state, however, that the 
signal transduction pathways from each of these inducers of apoptosis are different. For 
e:?{ample, triggering with an cxTCR mAb via the TCR/CD3 complex results in a signal 
which is transduced into the cytoplasm. This eventually raises the levels of intracellular 
calclum (Ca2+), an event believed to activate a Ca2+ -dependent endonuclease which then 
degrades the cellular DNA into 180-200 basepair (bp) oligonucleosomal fragments. 
Conversely, glucocorticoids, which are steroids, pass directly through the plasma 
membrane and bind to their glucocorticoid receptor near the nucleus, where they act as 
transcription factors and, sometimes, alter the levels of intracellular Ca2+. Therefore, 
glucocorticoids have the ability to bypass some of the earlier cytoplasmic signal-
transduction pathways. This example illustrates how two different agents, utilizing two 
different pathways, can lead to exactly the same outcome--apoptosis. This information 
can be extended to SUP-T13 cells in view of the apoptosis triggered by an cxFAS mAb 
or by a calcium ionophore. Not unlike the cxTCR mAb, both of these agents induce 
apoptosis in SUP-T13 cells. However, the cxCD3 mAb has the ability to rescue only the 
apoptosis induced by the cxTCR mAb, but not the apoptosis induced by either the cxFAS 
mAb or the calcium ionophore. This would indicate that more than one pathway for 
apoptosis induction exist in SUP-T13 cells. 
King et al. (1993) discuss the role of protein kinase C (PKC) in thymocyte 
apoptosis. One process which occurs when a ligand binds to its receptor (such as an 
cxTCR mAb to the TCR/CD3 complex) is the activation of phospholipase C (PLC), an 
enzyme which hydrolyses phosphoidylinositol-4,5-bisphosphate (PIP2), an integral 
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component of the plasma membrane, into inositol triphosphate (IP3) and diacylglycerol 
(DAG). IP3 causes the release of intracellular stores of calcium, which in tum have been 
shown to activate PKC. DAG is a physiological activator of PKC. The authors describe 
numerous reports which show conflicting data about the role of PKC in thymocyte 
apoptosis, with some showing that PKC activation is permissive to apoptosis, and others 
showing that it is antagonistic. One report even showed that simultaneous treatment with 
both PMA (a phorbol ester which activates PKC) and H7 (an inactivator of PKC) 
prevented the apoptosis induced by calcium ionophores (Kizaki et al., (1989). This 
report also demonstrates that it is extremely difficult to reach a consensus about 
apoptosis, even in regards to just one pathway. Similarly, recent work in our laboratory 
has shown that PMA increased the killing of SUP-T13 cells by the aTCR mAb and by 
a calcium ionophore, but it rescued apoptosis induced by the aF AS mAb (unpublished 
data). 
These types of reports indicate that there are still many missing links in our 
understanding of apoptosis, especially in regards to its molecular mechanisms. Until 
further work becomes available from the numerous ongoing studies in this field, the most 
plausible hypothesis which can be put forth is that many agents exist which can induce 
apoptosis. In tum, many different signalling pathways exist which eventually lead to 
apoptosis. It is very likely, therefore, that these signals are very divergent at the 
proximal extremes of the apoptotic pathway, and that they eventually converge much 
more distally in this pathway or, even possibly, that they activate independent apoptosis 
programs (Collins et al., 1993; Evans, 1993; and Schwartzman et al, 1993). 
CONCLUSION 
The data from this investigation negate Hypothesis One (H-1), which states that 
BCL-2 is involved in blocking SUP-T13 apoptosis. Therefore, there is no relationship 
between changes in BCL-2 expression levels and apoptosis induction in SUP-T13 cells, 
an in vitro model representing thymic selection. The conclusion that can be drawn is that 
changes in BCL-2 oncogene expression levels are not necessary for either the aCD3 
mAb-mediated rescue, or the aTCR mAb-induced apoptosis, in SUP-T13 cells. By 
inference, these findings can be extended to thymic selection in vivo, suggesting that 
BCL-2 may not have a role in that biological process. Lastly, multiple pathways to 
apoptosis exist in SUP-T13 cells, not all of which can be blocked by aCD3 mAb. 
Again, this finding can be extended to thymic selection in vivo, suggesting that it is under 
the control of more than one gene and/ or pathway. 
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